欧加农公司近日宣布，其补充新药申请已获得美国食品药品监督管理局（FDA）的批准。此次获批意味着Nexplanon®（依托孕烯植入剂）68毫克不透射线产品的使用期限得以延长。
欧加农公司近日宣布，其补充新药申请已获得美国食品药品监督管理局（FDA）的批准。此次获批意味着Nexplanon®（依托孕烯植入剂）68毫克不透射线产品的使用期限得以延长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.